ResMed Inc. 10-K Summary: Fiscal Year Ended June 30, 1999
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended June 30, 1999. ResMed Inc. is a leading designer, manufacturer, and distributor of medical equipment for treating and diagnosing sleep disordered breathing (SDB), primarily obstructive sleep apnea (OSA). The company operates globally with principal executive offices in San Diego, California, and primary manufacturing in Sydney, Australia. As of June 30, 1999, the company employed 477 individuals.
Key Financial Metrics
| Metric | Fiscal 1999 | Fiscal 1998 |
|---|---|---|
| Net Revenues | $88.6 million | $66.5 million |
| Gross Profit | $59.2 million | $43.5 million |
| Gross Margin | 66.8% | 65.3% |
| Net Income | $16.1 million | $10.6 million |
| Diluted EPS | $1.04 | $0.71 |
| Operating Cash Flow | $18.2 million | $6.8 million |
| Cash & Equivalents | $11.1 million | $15.5 million |
| Working Capital | $32.5 million | $32.8 million |
| Long-Term Debt | $0 | $0 (Current portion: $227k) |
Note: The company repaid its $870,000 Australian government loan facility during fiscal 1999.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 33% to $88.6 million, driven by higher unit sales of flow generators and accessories in the Americas (up to $51.0 million) and Europe (up to $30.2 million).
- Margin Expansion: Gross margin improved to 66.8% from 65.3%, attributed to manufacturing efficiencies and a shift toward higher-margin bilevel units (VPAP).
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 30% to $27.4 million due to a 54-person increase in sales and administrative staff. R&D expenses increased 31% to $6.5 million.
- Foreign Currency Impact: Foreign currency losses decreased to $2.5 million in 1999 from $4.0 million in 1998, improving "Other (expense) income" to a net loss of $0.7 million.
- Capital Expenditures: Significant investment in a new 120,000 sq. ft. manufacturing facility in Sydney resulted in a $9.9 million cash outflow, reducing cash and equivalents by $4.0 million year-over-year.
Outlook, Risks, and Management Commentary
- Product Innovation: The company introduced the AutoSet T home CPAP unit in March 1999, which automatically adjusts pressure. It also formed a strategic alliance with Critical Care Concepts Inc. to distribute products to the US hospital market.
- Legal Proceedings: ResMed is engaged in ongoing patent litigation against competitor Respironics Inc. in the US and Australia. While ResMed intends to appeal summary judgment rulings, there is uncertainty regarding potential damages and legal costs.
- Reimbursement Risks: Success depends on third-party payors (Medicare, Medicaid, private insurers) reimbursing patients. Managed care trends and price controls in foreign markets (e.g., Germany, France) pose risks to pricing power.
- Year 2000 Compliance: The company expects all information systems to be Y2K compliant by September 1999. Estimated costs for the Oracle implementation are $3.0 million, with Y2K specific costs at $100,000.
- Forward-Looking Statements: Management anticipates continued market growth due to increasing awareness of SDB and expanding applications for CPAP therapy (e.g., cardiac and stroke patients).
Investor Verification Checklist
- Verify the status and potential financial impact of the patent litigation against Respironics Inc.
- Monitor third-party reimbursement policies, particularly in the US and key European markets, for signs of price pressure or coverage restrictions.
- Assess the adoption rate and revenue contribution of the new AutoSet T product line.
- Review the company's foreign currency hedging strategy given the significant exposure to the Australian dollar.
- Confirm the operational readiness and cost efficiency of the new Sydney manufacturing facility.